Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Raised by GAMMA Investing LLC

GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 18,981.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 178,796 shares of the biopharmaceutical company's stock after acquiring an additional 177,859 shares during the period. GAMMA Investing LLC owned approximately 0.14% of Halozyme Therapeutics worth $114,090,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC increased its stake in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the period. Institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HALO shares. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Finally, Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded down $0.30 on Thursday, hitting $53.55. The stock had a trading volume of 1,963,774 shares, compared to its average volume of 1,651,833. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of 15.61, a P/E/G ratio of 0.42 and a beta of 1.26. The company's 50 day moving average price is $58.11 and its 200 day moving average price is $55.77.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. During the same period in the prior year, the business posted $0.79 EPS. The company's revenue for the quarter was up 35.2% on a year-over-year basis. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.